Progenics Pharmaceuticals is an oncology company focused on the development and commercialization of medicines and artificial intelligence to find, fight and follow cancer. Co.'s product candidates include: AZEDRA® (iobenguane I 131), which is a radiotherapeutic for the treatment of adult and pediatric patients 12 years and older with iobenguane scan positive or metastatic pheochromocytoma or paraganglioma who require systemic anticancer therapy; and 1095, which is a prostate-specific membrane antigen-targeted iodine-131 labeled small molecule that is designed to deliver a dose of beta radiation directly to prostate cancer cells with minimal impact on the surrounding healthy tissues. The PGNX average annual return 10 years is shown above.
The Average Annual Return on the PGNX average annual return 10 years page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether PGNX average annual return 10 years or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the PGNX average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|